Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gilgamesh Pharmaceuticals Inc. is currently managing 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of pending work is distributed across 7 distinct examiners, which suggests a broad range of individual oversight for the company's patent applications. The prosecution activity is further spread across 6 distinct art units, indicating that the technical subject matter spans several specialized groups within the patent office.
Sophia Jane Reilly is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action. Given that there are 7 pending office actions in total and 7 distinct examiners, the workload is distributed among many individuals. This distribution between 7 distinct examiners and 7 pending office actions, combined with the use of 6 distinct art units, reflects a decentralized prosecution strategy. Sophia Jane Reilly and the other examiners are working within 6 distinct art units to process the 1 pending office action assigned to the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| KLINKEL, KORTNEY L | 1 | 39.7% | +43.1% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18857979 | PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS | REILLY, SOPHIA JANE | — |
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18572861 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | KLINKEL, KORTNEY L | — |
| 18287980 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | VALLE, ERNESTO | — |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | — |
| 17714879 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1625 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1691 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857979 | PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS | REILLY, SOPHIA JANE | 1627 | §102§103§112DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18572861 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | KLINKEL, KORTNEY L | 1627 | §102Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18287980 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | VALLE, ERNESTO | 1623 | DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | 1626 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 17973119 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | RAHMANI, NILOOFAR | 1691 | §112 | Non-Final OA | 264d overdue | Pending | Oct 25, 2022 |
| 17714879 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | COPPINS, JANET L | 1628 | §112DP | Final Rejection | — | Pending | Apr 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGilgamesh Pharmaceuticals Inc. has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Sophia Jane Reilly has the most, with 1 of Gilgamesh Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
